Roche provided molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern
On Mar. 15, 2022, Roche announced available testing solutions that can identify the SARS-CoV-2 B.1.1.529 variant and differentiate…
On Mar. 15, 2022, Roche announced available testing solutions that can identify the SARS-CoV-2 B.1.1.529 variant and differentiate…
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by the Centers for Disease Control and…
On Mar. 10, 2022, a COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to…
On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
On Mar. 4, 2022, the WHO announced it had published an updated position paper on the RTS,S/AS01 (RTS,S)…
On Mar. 3, 2022, the World Health Organization (WHO) and the Medicines Patent Pool (MPP) jointly welcomed the announcement…
On Mar. 2, 2022, British Columbia officials announced it was working to prevent highly pathogenic avian influenza from infecting…
On Mar. 2, 2022, the Iowa Department of Agriculture and Land Stewardship and the United States Department of…
On Mar. 1, 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that two doses of Pfizer-BioNTech…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Feb. 18, 2022, the U.S. Centers for Disease Control and Prevention (CDC) released the 2022 recommended immunization…
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…